Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of tislelizumab for previously treated advanced urothelial carcinoma
ChiCTR2000033177Phase 4Not yet recruiting
- Sponsor
- Department of Urology, First Affiliated Hospital of Chongqing Medical University
- Start
- Jul 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in transitional cell carcinoma (TCC), sponsored by Department of Urology, First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Objective response rate. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2000033177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033177.